At a glance
- Originator GlaxoSmithKline; Ligand Pharmaceuticals
- Class
- Mechanism of Action Granulocyte colony-stimulating factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neutropenia
Most Recent Events
- 07 Feb 2001 Discontinued-Preclinical for Neutropenia in USA (Unknown route)
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 05 Jan 2000 Profile reviewed but no significant changes made